drugset / Trial / NCT01940562

Eltrombopag for Enhancing Platelet Engraftment in Pediatric Patients Undergoing Cord Blood Transplantation

NCT01940562

Phase 2 Unknown 20 enrolled moshe yeshurun GlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment

Summary

Platelet recovery is significantly hampered following umbilical cord blood transplantation (UCB). Thus, after UCB transplantations, patients are platelet transfusion-dependent for prolong periods of time. Eltrombopag is a thrombopoietin-receptor agonist that initiates thrombopoietin-receptor signaling and thereby induces proliferation and maturation of megakaryocytes. We will evaluate the safety and efficacy of eltrombopag for enhancing platelet engraftment in pediatric patients undergoing cord blood transplantation.

Timeline

Start
2013-10
Primary completion
2016-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Eltrombopag Small molecule 3.5 mg/kg
Subject Eltrombopag Small molecule 150 mg
Subject Eltrombopag Small molecule 200 mg